Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from GSK

Finally An Omicron-Blocking Shot? Sanofi, GSK Say Yes

Sanofi stock bounded higher Friday after its GSK-partnered Covid shot tamped down on omicron infections in a Phase 3 study.

Investors Business Daily

Sanofi-GSK's Beta-Containing COVID-19 Vaccine Shows Efficacy Against Omicron

Sanofi SA (NASDAQ:SNY) and GSK plc (NYSE:GSK) have announced positive data from their vaccine trial of adjuvanted bivalent D614 and Beta (B.1.351) vaccine candidate. "Sanofi-GSK's vaccine is the first candidate to demonstrate efficacy in a placebo-controlled trial in an environment of high Omicron variant circulation," Sanofi said in a statement. The bivalent vaccine targets the…

Benzinga

Kynos Therapeutics appoints chief finance officer

She will combine her current role as COO at NodThera while supporting the Edinburgh medtech firm

Insider UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Pharmaceutical giant GSK opens new £90m North East manufacturing site

The company says the opening of Q Block will allow the Barnard Castle site to strengthen its global role

Birmingham Post

Analyzing GSK's Short Interest

GSK's (NYSE:GSK) short percent of float has fallen 17.24% since its last report. The company recently reported that it has 6.02 million shares sold short, which is 0.24% of all regular shares that are available for trading.

Benzinga

Antibiotic Makers Adopt Their Own Environmental Safeguard Standards

The AMR Industry Alliance, a life-sciences coalition set up to provide sustainable solutions to curb antimicrobial resistance (AMR), is adopting its standards limiting toxic emissions. The Alliance published its Antibiotic Manufacturing Standard: Minimizing the risk of developing antibiotic resistance and aquatic ecotoxicity in the environment resulting from manufacturing human antibiotics. The…

Benzinga

Morning Brief: Top Financial Stories Dominating on Friday, June 10

Reuters Rebranded McDonald’s Restaurants To Reopen In Russia

Benzinga

Read news from The Economist, FT, and more,
with one subscription

GSK Shows Positive Pivotal Phase III Data For Its RSV Vaccine Candidate

GSK plc (NYSE:GSK) intends to engage with regulators immediately after reporting positive headline results from a pre-specified efficacy interim analysis of the AReSVi 006 phase III trial, it anticipates regulatory submissions in the second half of 2022. AReSVi 006 is a phase III trial investigating GSK’s respiratory syncytial virus (RSV) vaccine candidate…

Benzinga

Why the malaria vaccine took 35 years

Malaria's complex biology played a role in the delay, but experts say there was also a lack of urgency and funding

Salon

GSK Confirms Consumer Healthcare Unit Spin-off: What Investors Should Know

Close on the heels of an M&A deal, GlaxoSmithKline plc (NYSE: GSK) confirmed the spin-off of the consumer healthcare business it jointly owns with U.S. pharma giant Pfizer, Inc.

Benzinga

Morning Brief: Top Financial Stories Dominating on Wednesday, June 1

Reuters Redbird Capital Buys Italian Football Club AC Milan

Benzinga

Pfizer To Quit GSK's Consumer Health JV Following Its Spin-Off

Pfizer Inc. (NYSE:PFE) intends to sell its 32% investment in Haleon, a consumer health joint venture with GSK plc (NYSE:GSK), after the business is spun out as an independent listed company in July, reported Reuters. Pfizer had previously indicated that it might seek to sell its stake in Haleon, a consumer health company and…

Benzinga

Unilever Jumps After Nelson Peltz Joins Board

Unilever plc (NYSE: UL) shares traded higher by 8% on Tuesday after the company announced activist investor Nelson Peltz is joining the company's board of directors.

Benzinga

GlaxoSmithKline Announces $3.3 Billion Buyout To Square Off With Pfizer, Merck

GlaxoSmithKline announced Tuesday a $3.3 billion deal to buy pneumonia vaccine-maker Affinivax. But GSK stock dipped at the close.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

The Independent UK

GSK strikes deal to buy US vaccine firm Affinivax

It comes as the UK pharmaceutical business seeks to bolster its vaccine operation as part of a shake-up of its portfolio.

The Hindu

GSK looking to invest more in Hyderabad

KTR holds discussions with Global R&D Head of GSK Consumer Health in London

StockNews.com

3 Healthcare Stocks That Pay Dominant Dividends

Despite heightened market volatility, the healthcare industry is expected to grow significantly in 2022 amid surging chronic diseases worldwide, an aging population, increasing healthcare expenditure, and numerous medical advancements. So, we think it could be wise to invest in fundamentally sound healthcare stocks Gilead (GILD), Takeda (TAK), and GlaxoSmithKline (GSK).…

Benzinga

ARWR: Phase 3 PALISADE Study of ARO-APOC3 Underway…

By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

GlaxoSmithKline: Dividend Insights

Wednesday marks the last chance for investors to receive the next dividend payout from GlaxoSmithKline (NYSE:GSK).

The Guardian - UK

Hundreds of organisations breached patient data rules, reveals BMJ

Drug firms, private healthcare providers and universities among those that may be failing to protect confidentiality, says report

The Guardian - UK

Boots, Superdrug and other chemists report hay fever pill shortages

GlaxoSmithKline blames shortage of key ingredient for lack of Piriton and Piriteze tablets

StockNews.com

3 High-Yield Dividend Stocks to Buy in May: GlaxoSmithKline, A.P. Moeller-Maersk, and ENI

With the latest federal interest rate hike and the possibility of further monetary policy tightening, market indices have been going haywire. Because volatility is expected to persist, with experts fearing the economy will slip into recession, we think it could be wise to bet on high dividend-yielding stocks GlaxoSmithKline (GSK),…

Benzinga

GlaxoSmithKline Clocks 32% Topline Growth Buoyed By COVID-19 Therapy, Shingrix Vaccine

GlaxoSmithKline Plc's (NYSE:GSK) Q1 turnover reached £9.78 billion, up 32% Y/Y on actual exchange rate AER and constant exchange rate CER basis. Specialty Medicines turnover was £3.13 billion, up 98% AER, 97% CER (+16% AER, 15% CER excluding Xevudy), driven by consistent growth in all therapy areas, including sales of Xevudy. Sales…

Benzinga

Recap: GlaxoSmithKline Q1 Earnings

GlaxoSmithKline (NYSE:GSK) reported its Q1 earnings results on Wednesday, April 27, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Benzinga

GlaxoSmithKline's Earnings Outlook

GlaxoSmithKline (NYSE:GSK) is set to give its latest quarterly earnings report on Wednesday, 2022-04-27. Here's what investors need to know before the announcement. Analysts estimate that GlaxoSmithKline will report an earnings per share (EPS) of $0.76.

1 … 10 11 12 13

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations